# 18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer

> **NCT06414902** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 60 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** ArabinoFuranosylGuanine [18F]F-AraG

## Key facts

- **NCT ID:** NCT06414902
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-04
- **Primary completion:** 2027-10-01
- **Final completion:** 2027-10-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06414902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06414902, "18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06414902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*